Compare SEAT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEAT | MDXH |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 68.7M |
| IPO Year | 2021 | 2021 |
| Metric | SEAT | MDXH |
|---|---|---|
| Price | $4.93 | $0.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $18.06 | $7.67 |
| AVG Volume (30 Days) | 54.6K | ★ 16.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | $4.60 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.06 | $0.40 |
| 52 Week High | $18.73 | $5.33 |
| Indicator | SEAT | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 28.03 | 54.12 |
| Support Level | N/A | $0.68 |
| Resistance Level | $7.69 | $1.13 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 1.21 | 12.58 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.